Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment

The Covid-19 pandemic has caused millions of deaths worldwide. Although vaccines have been developed, patients on immunosuppressive therapy are less likely to respond. This study was aimed at investigating the efficacy of a Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Tvito, Ariella, Ronson, Aaron, Ghosheh, Renan, Kharit, Mira, Ashkenazi, Jakob, Magen, Sophie, Broide, Ellen, Benayoun, Emmanuel, Rowe, Jacob M., Ofran, Yishai, Ganzel, Chezi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691955/
https://www.ncbi.nlm.nih.gov/pubmed/34952139
http://dx.doi.org/10.1016/j.exphem.2021.12.396
_version_ 1784618856998764544
author Tvito, Ariella
Ronson, Aaron
Ghosheh, Renan
Kharit, Mira
Ashkenazi, Jakob
Magen, Sophie
Broide, Ellen
Benayoun, Emmanuel
Rowe, Jacob M.
Ofran, Yishai
Ganzel, Chezi
author_facet Tvito, Ariella
Ronson, Aaron
Ghosheh, Renan
Kharit, Mira
Ashkenazi, Jakob
Magen, Sophie
Broide, Ellen
Benayoun, Emmanuel
Rowe, Jacob M.
Ofran, Yishai
Ganzel, Chezi
author_sort Tvito, Ariella
collection PubMed
description The Covid-19 pandemic has caused millions of deaths worldwide. Although vaccines have been developed, patients on immunosuppressive therapy are less likely to respond. This study was aimed at investigating the efficacy of a Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma treated with anti-CD20 monoclonal antibodies. Only 1 of 28 lymphoma patients (3.6%) developed a seropositive response, compared with 100% (28/28) of the healthy volunteers. The low levels of CD19(+) lymphocytes among the lymphoma patients suggest that anti-CD20 treatment prevents the seropositive response to the vaccine. An additional vaccination might be indicated in these patients once B cells are repopulated.
format Online
Article
Text
id pubmed-8691955
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-86919552021-12-22 Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment Tvito, Ariella Ronson, Aaron Ghosheh, Renan Kharit, Mira Ashkenazi, Jakob Magen, Sophie Broide, Ellen Benayoun, Emmanuel Rowe, Jacob M. Ofran, Yishai Ganzel, Chezi Exp Hematol Brief Communication The Covid-19 pandemic has caused millions of deaths worldwide. Although vaccines have been developed, patients on immunosuppressive therapy are less likely to respond. This study was aimed at investigating the efficacy of a Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma treated with anti-CD20 monoclonal antibodies. Only 1 of 28 lymphoma patients (3.6%) developed a seropositive response, compared with 100% (28/28) of the healthy volunteers. The low levels of CD19(+) lymphocytes among the lymphoma patients suggest that anti-CD20 treatment prevents the seropositive response to the vaccine. An additional vaccination might be indicated in these patients once B cells are repopulated. ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. 2022-03 2021-12-22 /pmc/articles/PMC8691955/ /pubmed/34952139 http://dx.doi.org/10.1016/j.exphem.2021.12.396 Text en © 2021 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Brief Communication
Tvito, Ariella
Ronson, Aaron
Ghosheh, Renan
Kharit, Mira
Ashkenazi, Jakob
Magen, Sophie
Broide, Ellen
Benayoun, Emmanuel
Rowe, Jacob M.
Ofran, Yishai
Ganzel, Chezi
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment
title Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment
title_full Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment
title_fullStr Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment
title_full_unstemmed Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment
title_short Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment
title_sort anti-cd20 monoclonal antibodies inhibit seropositive response to covid-19 vaccination in non-hodgkin lymphoma patients within 6 months after treatment
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691955/
https://www.ncbi.nlm.nih.gov/pubmed/34952139
http://dx.doi.org/10.1016/j.exphem.2021.12.396
work_keys_str_mv AT tvitoariella anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT ronsonaaron anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT ghoshehrenan anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT kharitmira anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT ashkenazijakob anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT magensophie anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT broideellen anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT benayounemmanuel anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT rowejacobm anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT ofranyishai anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment
AT ganzelchezi anticd20monoclonalantibodiesinhibitseropositiveresponsetocovid19vaccinationinnonhodgkinlymphomapatientswithin6monthsaftertreatment

Ejemplares similares